[Source: Market Watch] – Peregrine Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, today announced data to be presented on June 6, 2010 at the ASCO Annual Meeting from a Phase I trial of Cotara(R) in patients with relapsed glioblastoma multiforme (GBM), the deadliest form of brain cancer. Cotara is a targeted monoclonal antibody linked to a radioisotope that is administered directly into the tumor, destroying the tumor from the inside out, with minimal exposure to healthy tissue. Final data from this dose confirmatory and radiation dosimetry trial confirm Cotara’s targeting capabilities, delivering 300-fold higher radiation levels to the tumor than to normal organs.
Glioblastoma Multiforme data reported at ASCO
June 3, 2010